AHR and myeloid sarcoma: In an experimental model of MS, DIM- and indole-3-carbinol (I3C)-activated Ahr were shown to inhibit clinical symptoms and cellular infiltration within the CNS by promoting the generation of Treg cells while suppressing myelin oligodendrocyte glycoprotein (MOG)-specific Th17 cells [19].